NORTH AMERICAN BIOLOGICALS, INC. – Trademark Portfolio

Entity Type: 03

NORTH AMERICAN BIOLOGICALS, INC. holds 19 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 13 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 4 Nice Classification classes. The owner is based in MIAMI, FL.

15960 NW. 15TH AVE.

MIAMI, FL 33169

19 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

NORTH AMERICAN BIOLOGICALS, INC.'s trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (13 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

42
Computer & Scientific (2 filings)

Scientific and technological services; industrial analysis and research services

10
Medical Apparatus (2 filings)

Surgical, medical, dental and veterinary apparatus and instruments

1
Chemicals (1 filing)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

Frequently Asked Questions

How many trademarks does NORTH AMERICAN BIOLOGICALS, INC. have?

NORTH AMERICAN BIOLOGICALS, INC. has 19 U.S. trademarks filed with the USPTO.

What trademark classes does NORTH AMERICAN BIOLOGICALS, INC. file in?

NORTH AMERICAN BIOLOGICALS, INC. files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 10 (Medical Apparatus), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What is NORTH AMERICAN BIOLOGICALS, INC.'s trademark registration success rate?

NORTH AMERICAN BIOLOGICALS, INC. has a 0% trademark registration rate, with 0 out of 19 resolved applications resulting in successful registration. Currently, 0 applications are pending review.